Lidocaine Hcl

Verify with FDA CVM →

83 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
83
Total Reports
21
Deaths Reported
2530.0%
Death Rate

Active Ingredients

Lidocaine Hcl

Administration Routes

UnknownOtherIntravenousSubcutaneousTopicalIntradermalIntra-ArticularParenteral

Species Affected

Dog 41
Cat 20
Cattle 16
Horse 5
Rabbit 1

Most Affected Breeds

Holstein-Friesian also known as Holstein 14
Domestic Shorthair 10
Retriever - Labrador 3
Siamese 3
Domestic Mediumhair 3
Retriever - Golden 3
Dachshund (unspecified) 2
Spaniel (unspecified) 2
Great Pyrenees 2
Cat (unknown) 2

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 16
Other abnormal test result NOS 11
Anorexia 11
Death by euthanasia 11
Vomiting 9
Death 9
Injection site swelling 9
Emesis 6
Cardiac arrest 6
Ataxia 6
Pale mucous membrane 5
Anaemia NOS 4

Outcome Breakdown

Recovered/Normal
26 (31.3%)
Ongoing
25 (30.1%)
Euthanized
11 (13.3%)
Died
10 (12.0%)
Recovered with Sequela
6 (7.2%)
Outcome Unknown
5 (6.0%)

Data Summary

Metric Value
Total adverse event reports 83
Reports involving death 21
Case-fatality rate (reported events) 2530.0%
Distinct species in reports 5
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Lidocaine Hcl Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 83 adverse event reports referencing Lidocaine Hcl, including 21 reports in which the animal died — a 2530.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Lidocaine Hcl. Reported administration routes include Unknown, Other, Intravenous, Subcutaneous. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Lidocaine Hcl reports are Dog (41 reports), Cat (20 reports), Cattle (16 reports), with Dog accounting for the largest share. Within those species, Holstein-Friesian also known as Holstein (14), Domestic Shorthair (10), Retriever - Labrador (3) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Lidocaine Hcl are Lethargy (see also Central nervous system depression in 'Neurological') (16), Other abnormal test result NOS (11), Anorexia (11), Death by euthanasia (11). Of the 83 reports with a coded outcome, Recovered/Normal is the leading category at 31.3%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Lidocaine Hcl.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial